Health Economics›Acute myeloid leukemia›Consolidation after upfront therapy

Consolidation after upfront therapy

Acute myeloid leukemia · 35 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Azacitidine and Gemtuzumab ozogamicin Variant #01	—	R 72 311	8d	—	—	~1	~R 72 311 indirect	—
Cytarabine, Daunorubicin, Gemtuzumab ozogamicin Variant #01	—	R 61 046	—	—	—	~2	~R 110 265 indirect	—
HiDAC and Midostaurin Variant #01	FLT3	R 52 202	28d	—	—	~4	~R 208 810 indirect	—
Cytarabine, Idarubicin, Sorafenib Variant #01	—	R 30 951	42d	—	—	~5	~R 154 754 indirect	—
Busulfan and Fludarabine, then allo HSCT Variant #08 Partial	—	R 30 308	—	~9.0 mo	—	~1	~R 30 308 PFS proxy · indirect	2
Azacitidine monotherapy Variant #01	—	R 29 332	28d	—	~8.7 mo	~6	~R 175 992 PFS proxy · indirect	11
IDAC and Sorafenib Variant #01	FLT3	R 29 098	42d	—	—	~2	~R 58 196 indirect	—
Amsacrine and HiDAC Variant #01 Partial	—	R 27 987	—	—	—	~1	~R 27 987 indirect	—
HiDAC and G-CSF Variant #01	—	R 24 168	35d	—	—	~3	~R 72 504 indirect	—
CLARA Variant #01 Partial	—	R 19 971	35d	—	—	~1	~R 19 971 indirect	—
4i+7 Variant #01	—	R 18 769	—	—	—	~1	~R 18 769 indirect	—
Cytarabine and Daunorubicin Variant #01	—	R 18 067	30d	—	—	~2	~R 24 307 indirect	—
Clofarabine and LoDAC/Decitabine Variant #01 Partial	—	R 16 664	49d	—	—	~9	~R 148 106 indirect	—
Fludarabine and TBI, then allo HSCT Variant #01 Partial	—	R 16 505	—	—	—	~1	~R 16 505 indirect	—
HAM Variant #01	—	R 15 692	—	—	—	~1	~R 15 692 indirect	—
4d+7 Variant #01	—	R 13 076	—	—	—	~1	~R 13 076 indirect	—
Cytarabine and Idarubicin Variant #01	—	R 12 853	30d	—	—	~1	~R 12 853 indirect	—
Etoposide and Mitoxantrone Variant #01	—	R 12 244	—	—	—	~1	~R 12 244 indirect	—
5+2i Variant #01	—	R 12 171	5d	—	—	~1	~R 12 171 indirect	—
CIA Variant #01 Partial	—	R 9 614	5d	—	—	~6	~R 57 686 indirect	—
Cytarabine, Idarubicin, Vorinostat Variant #01 Partial	—	R 9 614	28d	—	—	~5	~R 48 071 indirect	—
HiDAC and ATRA Variant #01	NPM1	R 7 776	—	—	—	~3	~R 23 328 indirect	—
IC and Norethandrolone/6-MP, MTX, Norethandrolone Variant #01 Partial	—	R 7 136	60d	—	—	~3	~R 21 409 indirect	—
HiDAC and Quizartinib Variant #01 Partial	FLT3	R 6 997	—	—	—	~4	~R 27 987 indirect	—
Busulfan and Cyclophosphamide Variant #01	—	R 6 777	—	—	—	~1	~R 6 777 indirect	—
5+2d Variant #01	—	R 6 360	5d	—	—	~1	~R 6 360 indirect	—
Cytarabine and Etoposide (CYVE) Variant #06	—	R 4 351	—	—	~9.2 mo	~2	~R 8 701 PFS proxy · indirect	—
High-dose Cytarabine monotherapy (HiDAC) Variant #01	—	R 3 498	—	—	60.0 mo	1	R 3 498 PFS proxy	—
Intermediate-dose Cytarabine monotherapy (IDAC) Variant #01	—	R 1 560	28d	—	~7.6 mo	~6	~R 9 359 PFS proxy · indirect	1
Cyclophosphamide and TBI, then allo HSCT Variant #01 Partial	—	R 1 176	—	—	—	~1	~R 1 176 indirect	—
Cytarabine monotherapy Variant #01	—	R 357	30d	—	—	~2	~R 713 indirect	—
Low-dose TBI, then allo HSCT Variant #01 Partial	—	—	—	—	—	~1	—	—
BuCy Partial	—	—	—	—	—	—	—	—
CPX-351 monotherapy Variant #01 Partial	—	—	49d	—	~9.3 mo	~1	—	1
Fludarabine, Busulfan, ATG, then allo HSCT Partial	—	—	—	—	—	—	—	—

35 of 35 regimens shown